PATENT CLAIM ANALYSIS

Application Number: 15888350
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-06
Patent Classification: ["514", "04400A"]

Abstract:
The invention relates to methods and uses of modulating fetal hemoglobin expression (HbF) in a hematopoietic progenitor cells via inhibitors of BCL11A expression or activity, such as RNAi and antibodies.

Claim (Index 28):
A method for identifying a modulator of BCL11A activity or expression, the method comprising contacting a hematopoietic progenitor cell with a composition comprising a test compound, and measuring the level of fetal hemoglobin or fetal hemoglobin mRNA in said cell or its progeny, wherein an increase in fetal hemoglobin is indicative that said test compound is a candidate inhibitor of BCL11A activity or expression.

Metadata:
- Claim Count in Document: 86.0
- Percentile: 88.0
- Lexical Diversity: 1.09677
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13063524', '13743399', '14647547', '15816083', '13992669']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8118183955066505
- 35 USC 102 Novelty (BERT): 0.7129213230118581
- Combined Prediction Score: 0.8019286882571712
- Mean Citation Score: 635.224112
- Max Citation Score: 823.47217
- Similarity Product: 735.4458119065839

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test